Tofacitinib also reduced the expression of MMP-1, MMP-3, CCL2, CXCL10, and CXCL13 in synovial biopsies of RA patients with an inadequate response to methotrexate [19]. This evidence concerns the gene CCL2 and rheumatoid arthritis.